Rhumbline Advisers Ardelyx, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

A detailed history of Rhumbline Advisers transactions in Ardelyx, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 326,124 shares of ARDX stock, worth $1.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

326,124

Previous 320,054 1.9%

Holding current value

$1.74 Million

Previous $2.21 Million 23.54%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 30, 2025	BUY	$4.49 - $6.85 $27,254 - $41,579	6,070 Added 1.9%	326,124 $1.69 Million
Q3 2024 Nov 12, 2024	SELL	$5.28 - $7.57 $94,580 - $135,601	-17,913 Reduced 5.3%	320,054 $2.21 Million
Q2 2024 Aug 01, 2024	BUY	$5.89 - $9.31 $2,314 - $3,658	393 Added 0.12%	337,967 $2.5 Million
Q1 2024 May 09, 2024	BUY	$6.05 - $9.74 $65,400 - $105,289	10,810 Added 3.31%	337,574 $2.46 Million
Q4 2023 Feb 08, 2024	BUY	$3.29 - $6.64 $73,432 - $148,204	22,320 Added 7.33%	326,764 $2.03 Million
Q3 2023 Nov 09, 2023	BUY	$3.3 - $4.83 $30,191 - $44,189	9,149 Added 3.1%	304,444 $1.24 Million
Q2 2023 Aug 08, 2023	BUY	$3.23 - $4.95 $953,802 - $1.46 Million	295,295 New	295,295 $1 Million
Q2 2022 Aug 11, 2022	SELL	$0.51 - $1.17 $49,970 - $114,637	-97,981 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$0.65 - $1.18 $1,830 - $3,322	2,816 Added 2.96%	97,981 $105,000
Q4 2021 Feb 10, 2022	SELL	$0.86 - $1.7 $2,064 - $4,080	-2,400 Reduced 2.46%	95,165 $105,000
Q3 2021 Nov 12, 2021	BUY	$1.27 - $8.17 $4,305 - $27,696	3,390 Added 3.6%	97,565 $129,000
Q2 2021 Aug 05, 2021	BUY	$6.55 - $8.98 $59,146 - $81,089	9,030 Added 10.61%	94,175 $714,000
Q1 2021 May 06, 2021	SELL	$6.1 - $7.69 $63,927 - $80,591	-10,480 Reduced 10.96%	85,145 $564,000
Q4 2020 Feb 10, 2021	BUY	$5.05 - $7.1 $53,227 - $74,834	10,540 Added 12.39%	95,625 $619,000
Q3 2020 Nov 12, 2020	SELL	$5.25 - $7.08 $70,166 - $94,624	-13,365 Reduced 13.58%	85,085 $447,000
Q2 2020 Aug 13, 2020	BUY	$5.37 - $8.11 $8,876 - $13,405	1,653 Added 1.71%	98,450 $681,000
Q1 2020 May 06, 2020	BUY	$4.35 - $8.79 $98,201 - $198,434	22,575 Added 30.42%	96,797 $550,000
Q4 2019 Feb 05, 2020	BUY	$4.23 - $8.29 $4,158 - $8,149	983 Added 1.34%	74,222 $557,000
Q3 2019 Oct 23, 2019	BUY	$2.15 - $6.28 $12,947 - $37,818	6,022 Added 8.96%	73,239 $344,000
Q2 2019 Aug 14, 2019	BUY	$2.49 - $3.73 $16,536 - $24,770	6,641 Added 10.96%	67,217 $181,000
Q1 2019 May 01, 2019	BUY	$1.88 - $3.35 $1,981 - $3,530	1,054 Added 1.77%	60,576 $170,000
Q4 2018 Jan 31, 2019	BUY	$1.66 - $4.16 $37,658 - $94,373	22,686 Added 61.59%	59,522 $107,000
Q3 2018 Nov 07, 2018	BUY	$3.75 - $4.65 $14,100 - $17,484	3,760 Added 11.37%	36,836 $160,000
Q2 2018 Aug 06, 2018	BUY	$3.7 - $5.8 $1,091 - $1,711	295 Added 0.9%	33,076 $122,000
Q1 2018 May 02, 2018	SELL	$5.05 - $7.9 $9,595 - $15,010	-1,900 Reduced 5.48%	32,781 $166,000
Q4 2017 Feb 09, 2018	SELL	$4.85 - $7.8 $31,888 - $51,285	-6,575 Reduced 15.94%	34,681 $229,000
Q3 2017 Nov 06, 2017	BUY	$4.35 - $5.7 $179,463 - $235,159	41,256	41,256 $231,000

Others Institutions Holding ARDX

# of Institutions

233

Shares Held

150M

Call Options Held

1.54M

Put Options Held

3.08M

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $824M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Ardelyx, Inc. Transaction History